000 02005nam  2200373za 4500
0019.852787
003CaOODSP
00520230313122855
007cr |||||||||||
008180302s2018    oncd    o    f000 0 eng d
020 |a9780660255125
040 |aCaOODSP|beng
043 |an-cn---
0861 |aH13-9/6-2018E-PDF
24500|aGuidance document |h[electronic resource] : |bconduct and analysis of comparative bioavailability studies.
24630|aConduct and analysis of comparative bioavailability studies
24617|aConduct & analysis of comparative bioavailability studies
260 |aOttawa : |bHealth Canada, |c2018.
300 |a35 p. : |bcharts.
500 |aIssued also in French under title: Ligne directrice : conduite et analyse des études de biodisponibilité comparatives.
500 |aCover title.
500 |a"Date adopted: 2012/02/08. Revised date: 2018/06/08. Effective date: 2018/09/01 (for submissions filed on or September 1, 2018)."
500 |a"Publication date: June 2018."
500 |aIssued also in HTML format.
520 |a"Policy objectives: To provide sponsors of new drug submissions with the information necessary to comply with Sections C.08.002(2)(h), C.08.002.1(2)(c)(ii) and C.08.003(3) of the Food and Drug Regulations (Regulations) with respect to comparative bioavailability studies used in support of the safety and efficacy of a drug"--Introd., p. 9.
693 4|aDrug approval
693 4|aDrugs--Bioavailability
693 4|aHandbooks
7101 |aCanada. |bHealth Canada.
77508|tLigne directrice |w(CaOODSP)9.852793
794 |tGuidance document : |w(CaOODSP)9.919266
85640|qPDF|s689 KB|uhttps://publications.gc.ca/collections/collection_2018/sc-hc/H13-9-6-2018-eng.pdf
8564 |qHTML|sN/A|uhttps://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/bioavailability-bioequivalence/conduct-analysis-comparative.html